跳至主要内容
临床试验/jRCT2080222691
jRCT2080222691已完成3 期

An Asian, phase 3, multicenter, randomized, double-blind, placebo-controlled 14-week study of DS-5565 in patients with post-herpetic neuralgia followed by a 52-week open-label extension

DAIICHISANKYO Co.,Ltd.1 个研究点目标入组 750 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
750
试验地点
1
主要终点
-

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
干预模型
A Double-blind Study Followed By Open-label Extension
主要目的
Treatment Purpose

入排标准

年龄范围
20age old over 至 No limit(—)
性别
All

入选标准

  • Post-herpetic neuralgia defined as pain present for more than 3 months after herpes zoster skin rash
  • Average daily pain score >= 4

排除标准

  • Previous use of neurolytic block (eg, chemical neurolytic block using phenol or ethyl alcohol, radiofrequency thermocoagulation) or neurosurgical therapy for current post-herpetic neuralgia
  • Other severe pain at screening or randomization, unrelated to post-herpetic neuralgia, that may confound the assessment of post-herpetic neuralgia
  • Neurologic disorders at screening or randomization, unrelated to post-herpetic neuralgia, that may confound the assessment of post-herpetic neuralgia

结局指标

主要结局

-

efficacy confirmatory Average daily pain score

次要结局

未报告次要终点

研究者

发起方
DAIICHISANKYO Co.,Ltd.

研究点 (1)

Loading locations...

相似试验